Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057379 · ClinicalTrials.gov registry record · NA
HPV IIS Reminder/Recall- New York State
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 30,616
- Enrollment target
NCT03057379: Completed NA study, sponsored by University of California, Los Angeles.
NCT03057379 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 30,616 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2082% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03057379, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 30,616 participants
- Enrollment target
Study Summary
The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve Human Papiloma Virus (HPV) vaccination rates among adolescents ages 11-17.
Primary Outcome
Did the adolescent initiate the HPV vaccine series? The investigators are allowing up to 5 months after the initial recall notice for the adolescent to make an appointment and receive their dose. After that time frame, the investigators will not attribute vaccination to the recall. Receipt will be documented by providers within the state immunization registry via electronic medical record (EMR) direct transfer or manual entry.
Interventions
- OTHER Vaccine Reminder Recall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,616 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2019-01-17 |
| Phase | NA |
What the finished NCT03057379 record still lists
NCT03057379 is an interventional study that assigns participants to a tested intervention. Its 30,616 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (2082% higher).
The record links to 0 conditions, and to 1 intervention - of which Vaccine Reminder Recall is the first listed.
NCT03057379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03057379 about?
NCT03057379 is a clinical study titled "HPV IIS Reminder/Recall- New York State". The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve Human Papiloma Virus (HPV) vaccination rates among adolescents ages 11-17.
What is the current status of trial NCT03057379?
This trial is currently completed. It is a NA study. The enrollment target is 30,616 participants. The study started on 2017-02-27. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT03057379?
The interventions under investigation include: Vaccine Reminder Recall (OTHER).
Who is sponsoring clinical trial NCT03057379?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03057379's enrollment target sits among peer trials
30,616 8th of 2000 higher than 1,993 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI